iBio Inc (IBIO)

Another financing deal in place. Integrated Core Strategies purchases 5.2% of Ibio shares.  
They are well financed now with plenty of runway and a strong drug development pipeline.  They should be a prime acquisition / partnership target for a major pharmaceutical that wants to boost their drug discovery pipeline.  

In the last month (Dec '25), 4 investment firms have taken significant stakes in Ibio:
Logos Capital: 8.9%EcoR1: 9.9%Frazier Life Sciences: 8.7%Affinity Asset: 9.99%Total % recently acquired: 37.49%
According to Yahoo Finance 55.78% of shares were already held by institutions before these recent purchases, but I question everything from Yahoo. 
Ibio's "Ibio-610" drug candidate for targeted weight loss would make an excellent target acquisition / partnership for companies like Pfizer, Sanofi, J&J, etc who badly want to compete with Eli Lilly and Novo Nordisk in the lucrative weight loss market. 
Hopefully 2026 will be a big year for Ibio.  
JMHO

High 3.82 back to 6.00

Still going 

2.38

Bids filling under 1.70

News out ?What's going on ?I'm out since 2 weeks.wtf 😳 

2.32 out early seee if it pulls back again

Out 1.80s

1.57

Let pump again $1.46

Same game since weeks ago.Hit 2 in Pre, than dilution or so.Finally red at the end of the day

ibio......................................https://stockcharts.com/sc3/ui/?s=IBIO&p=W&b=5&g=0&id=p86431144783

$2+ 😃

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025

https://markets.businessinsider.com/news/stocks/ibio-unveils-new-non-human-primate-data-on-ibio-610-an-activin-e-antibody-with-strong-therapeutic-potential-for-fat-selective-weight-loss-and-weight-maintenance-1035455212

$IBIO 💹

📉⤵️🤔

🚀🌙💲💲💲💲💲💲💲💲💲💲💲💲💲

$1.92 November 4-7 conference fat talks cash out time 

IBIO................................................https://stockcharts.com/sc3/ui/?s=IBIO&p=W&b=5&g=0&id=p86431144783

IBIO ☝️🥳☝️🚀🌙💲

Go up in anticipation of the presentation?

Nice start of the day $1.25 😃

$IBIO 💹

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025

iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta. In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon.

“We are excited to share additional data from the non-human primates study of our Activin E antibody, IBIO-610, which continues to support its potential as a differentiated approach to the treatment of obesity,” said Dr. Brenner. “These findings add to a growing body of research that inhibiting Activin E signaling could deliver fat-selective weight loss, support long-term weight maintenance, and enhance the benefits of GLP-1 therapies. These data suggest IBIO-610 could help overcome key limitations of current therapies and advance the next generation of cardiometabolic therapies.”

Obesity Week Presentation Details:
Title: Discovery and Testing of a First-in-Class Activin E Antagonist Antibody for the Treatment of Obesity

Date: November 4, 2025
Time: 2:00 p.m. – 2:15 p.m. EST
Presenter: Cory Schwartz, Director of Research and Early Development, iBio
Location: A411-A412

Dr. Schwartz will also present a poster titled “Preclinical Evaluation of a Long-Acting Anti-Myostatin Therapy for Obesity” on November 5 at 2:30 p.m. EST

To view the full agenda please visit https://obesityweek.org/attend/program/

PEGS Europe Presentation Details:
Title: A First-in-Class Anti-Activin E Antibody Induces Fat-Selective Weight-Loss in Diet-Induced Obese Mice

Date: November 12, 2025
Time: 11:45 a.m. – 12:15 p.m. WET
Presenter: Martin Brenner, CEO and CSO, iBio
Location: Podium Presentation
To view the full agenda please visit https://www.pegsummiteurope.com/

About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.

https://investorshub.advfn.com/stock-market/NASDAQ/ibio-IBIO/stock-news/97045974/ibio-to-present-new-preclinical-data-on-its-activi

$IBIO

IBIO.............................https://stockcharts.com/h-sc/ui?s=IBIO&p=W&b=5&g=0&id=p86431144783

iBio initiated with an Outperform at Oppenheimer

Oct 21, 2025

Oppenheimer initiated coverage of iBio (IBIO) with an Outperform rating and $5 price target The firm based its Outperform rating on its optimism for lead asset IBIO-610 to address key therapeutic challenges in the growing obesity market. Preclinical data validate the potential of 610 to drive both fat loss and lean mass preservation, supporting a highly differentiated and complementary profile vs. incumbent incretins, the analyst tells investors in a research note.

https://www.msn.com/en-us/money/other/ibio-initiated-with-an-outperform-at-oppenheimer/ar-AA1OQr3g

$IBIO

☝️🥳☝️

☝️🥳☝️

Another $50M-$100M worth of dilution on a stock with a $15M market cap. That's gonna leave a mark.

Today's Hot Stock Recommendations: $IBIO Price: $0.7124

Key resistance levels are $1.09 and $1.20-1.30, with support at $0.98. Set a stop loss

If it can break through $1.09, it may further test $1.50 or higher ($3.04 gap)$IBIO Rated "Strong Buy" pic.twitter.com/QPQzwklYA7— Stock trader David (@David_20078) June 24, 2025

$IBIO Running — Congrats. If You’re Looking for the Next Sleeper w/ Real Revenue, Take a Look at $RMTG

Big shoutout to those catching the $IBIO bounce today — it’s nice to finally see some green. I know a lot of people here have been patient.

That said, if you’re on the hunt for what could run next — but with real fundamentals behind it — take a look at $RMTG:
• ✅ 26 active clinics
• 🌎 21 countries
• 💵 Three straight profitable quarters
• 🔒 Only ~11.5M float
• 💥 Trading under $0.05
• 🧬 Regenerative medicine (stem cells + peptides)
• 📞 And yes — we can arrange a direct call with the CEO

No toxic dilution. Just real cash flow and expansion — and most people haven’t even heard of it yet.

If $IBIO heats up, this whole space gets more eyes. And $RMTG might be the one nobody saw coming.

— Andrew

ibio....................................................................................P/M

11.3 million shares at .85...  (IBIO) filed a preliminary prospectus for the sale of up to around 11.3 million shares of its common stock by certain selling stockholders.The shares are issuable upon the exercise of warrants sold to the selling stockholders in a private placement completed on April 30, the company said.The warrants have an exercise price of $0.86 per share and will expire five years after issuance, iBio said.The company said that it will not receive any of the proceeds from the sale of the shares, but will receive approximately $9.7 million in cash if the warrants are exercised in full. This will be used for working capital and general corporate purposes, the company added....

IBIO.........................................................................................................a/h

Wegovy style without muscle loss in chimps 

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

June 23, 2025

https://ih.advfn.com/stock-market/NASDAQ/ibio-IBIO/stock-news/96290955/ibio-presents-next-generation-obesity-and-cardiome

$IBIO 💹

Imagine all the IBIO investors that lost money following his investment advice he posted on this board and others telling people to Buy Buy Buy all without a license to do so.

Maybe on the advice of his attorney he changed his board name to run and hide hoping to dodge any repercussions.

Prolly only a matter of time before fake stock analyst get pulled into a class action.

Here's the really sad part. Had the fake stock analyst invested that $20K equally into the Magnificent 7 stocks (Alphabet/Google, Amazon, Apple, Meta, Microsoft, Nvidia, and Tesla) on July 28, 2020, and reinvested dividends, that $20K investment would now be worth $79,810 today, which is an annual return of 33.42%.

The fake stock analyst would do much better in reputable companies listed on major exchanges, instead of peddling in penny stocks. I imagine that's true for most investors. I've certainly learned my lesson. No more penny stocks for me, EVER.

Results from Portfolio Backtester
https://testfol.io

IBIO conducted 2 reverse splits after JPetro/Rotten Johnny's $20K investment in July 2020.

1-for-25 reverse split on 10/10/22
1-for-20 reverse split on 11/29/23

The 4,000 shares costing $20,000 are now 8 shares valued at $6.32 at the $0.79 closing price.

He's probably still holding these shares at the advice of his attorney. 😂

Daytrade wisely set those stop losses move up to .76 now 

.72 cents and  3.5m shares at .86 on warrants becoming more buyable as GLP-1 without muscle loss is the new  fad in Wegovy Ozempia style weight loss shots. Someone will buy them out if results continue positively 

Rotten Johnny
Tuesday, July 28, 2020

Post# 24016 of 27647
picked up 4k at $5

good to go as this will move North nicely from LOD

How many reverse splits was that ago?

a fool and his money are easily parted

IBIO back in delisting territory. Another great stock pick by the fake analyst, who will certainly be posting "BUY! BUY! BUY!" after IBIO undergoes the 4th reverse split in 7 years.

I wonder if the fake analyst was still invested in Rite Aid when they recently announced their second bankruptcy, where all common stock is cancelled, resulting in 100% loss for common shareholders. On a positive note, his IBIO shares are only down 99.9875% so not a total loss like Rite Aid, and according to his posts he still holds 100% of his AMBS shares from his six-figure investment there. AMBS never did a reverse split, so that loss is only 99.8%.

Where did the fake stock analyst get his investment training? Was he awake or even present during the classes. Probably skipped classes to go surfing, and giving beachgoers a good laugh.

Hey wait a second. The ticker doesn't say $6 something anymore.

The IBIO stock analyst is gonna freak when he finds out the stock lost another 80% since he was last PUMP'n it.

Averaging down prolly was a bad decision for him/her.

iBio Raises $6.2 Million Through Warrant Inducement Transaction

More dilution and if IBIO can't stay above a buckaroo...

Then a 4th RS.

About time for the fake stock analyst to post another BUY BUY BUY recommendation for IBIO. Be sure to ask him about his 99.8% loss in his IBIO shares after 3 reverse splits in the last 7 years.

The stock analyst was giving out BAD financial advice to average down and turns out he is not certified to advise anyone on financial investing.

Wonder some IBIO investors that lost significant money will sue.

Could easily get some of the ambulance chaser companies involved

IBIO printing $0.70

The fake stock analyst is silent. Rest assured if the price rises significantly he will post that he was buying a ton of IBIO shares at this range.

And no one will believe him. If IBIO was such a great buy in the $3 to $6 range, why no posts about buying down here?

Probably because it wouldn't matter. This stock cannot go high enough to recover the 99.9975% losses.

iBIO, new 52 week low

IBIO, new 52;week low

Down almost 10% today.

The poster that was telling everyone to buy the stock without a license to do so should be prosecuted in my opinion and force to pay damages to other shareholders.

Can’t even get a bite of pizza for 1 IBIO share. Glad I didn’t listen to the fool.

IBIO now in delisting territory again. Looks like a 4th reverse split in 7 years is inevitable. I would hate to be an investor who has been loading up on IBIO shares over the last few years... down 99.75% and soon to be down 99.9975%. The ones who post BUY BUY BUY!!

So far the move to NASDAQ is very telling — it couldn't hide the underlying weakness of the company's business model. While being promoted as a move that would enable access to more technically-oriented investors, it appears they have no interest in IBIO, as the stock has steadily declines since the switch to NASDAQ.